192 related articles for article (PubMed ID: 18065502)
1. Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice.
Siu EC; Tyndale RF
J Pharmacol Exp Ther; 2008 Mar; 324(3):992-9. PubMed ID: 18065502
[TBL] [Abstract][Full Text] [Related]
2. Mechanism-based inactivation of cytochrome P450 2A6 by decursinol angelate isolated from Angelica Gigas.
Yoo HH; Lee MW; Kim YC; Yun CH; Kim DH
Drug Metab Dispos; 2007 Oct; 35(10):1759-65. PubMed ID: 17620343
[TBL] [Abstract][Full Text] [Related]
3. Nicotine metabolism and urinary elimination in mouse: in vitro and in vivo.
Raunio H; Pokela N; Puhakainen K; Rahnasto M; Mauriala T; Auriola S; Juvonen RO
Xenobiotica; 2008 Jan; 38(1):34-47. PubMed ID: 18098062
[TBL] [Abstract][Full Text] [Related]
4. Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
Rahnasto M; Raunio H; Poso A; Wittekindt C; Juvonen RO
J Med Chem; 2005 Jan; 48(2):440-9. PubMed ID: 15658857
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of comparative molecular field analysis modelling of naphthalene inhibition of human CYP2A6 and mouse CYP2A5 enzymes.
Asikainen A; Tarhanen J; Poso A; Pasanen M; Alhava E; Juvonen RO
Toxicol In Vitro; 2003 Aug; 17(4):449-55. PubMed ID: 12849728
[TBL] [Abstract][Full Text] [Related]
6. Effect of grapefruit juice on cytochrome P450 2A6 and nicotine renal clearance.
Hukkanen J; Jacob P; Benowitz NL
Clin Pharmacol Ther; 2006 Nov; 80(5):522-30. PubMed ID: 17112808
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of neurotransmitters and steroids on human CYP2A6.
Higashi E; Nakajima M; Katoh M; Tokudome S; Yokoi T
Drug Metab Dispos; 2007 Apr; 35(4):508-14. PubMed ID: 17237153
[TBL] [Abstract][Full Text] [Related]
8. Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes.
Taavitsainen P; Anttila M; Nyman L; Karnani H; Salonen JS; Pelkonen O
Pharmacol Toxicol; 2000 May; 86(5):215-21. PubMed ID: 10862503
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro.
Zhang W; Kilicarslan T; Tyndale RF; Sellers EM
Drug Metab Dispos; 2001 Jun; 29(6):897-902. PubMed ID: 11353760
[TBL] [Abstract][Full Text] [Related]
10. Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism.
von Weymarn LB; Brown KM; Murphy SE
J Pharmacol Exp Ther; 2006 Jan; 316(1):295-303. PubMed ID: 16188955
[TBL] [Abstract][Full Text] [Related]
11. Characterization and comparison of nicotine and cotinine metabolism in vitro and in vivo in DBA/2 and C57BL/6 mice.
Siu EC; Tyndale RF
Mol Pharmacol; 2007 Mar; 71(3):826-34. PubMed ID: 17158199
[TBL] [Abstract][Full Text] [Related]
12. P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine.
Benetton SA; Fang C; Yang YO; Alok R; Year M; Lin CC; Yeh LT
Drug Metab Pharmacokinet; 2007 Apr; 22(2):78-87. PubMed ID: 17495414
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.
Draper AJ; Madan A; Parkinson A
Arch Biochem Biophys; 1997 May; 341(1):47-61. PubMed ID: 9143352
[TBL] [Abstract][Full Text] [Related]
14. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes.
Messina ES; Tyndale RF; Sellers EM
J Pharmacol Exp Ther; 1997 Sep; 282(3):1608-14. PubMed ID: 9316878
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of nicotine metabolism by methoxysalen: Pharmacokinetic and pharmacological studies in mice.
Damaj MI; Siu EC; Sellers EM; Tyndale RF; Martin BR
J Pharmacol Exp Ther; 2007 Jan; 320(1):250-7. PubMed ID: 17021260
[TBL] [Abstract][Full Text] [Related]
16. Role of human cytochrome P4502A6 in C-oxidation of nicotine.
Nakajima M; Yamamoto T; Nunoya K; Yokoi T; Nagashima K; Inoue K; Funae Y; Shimada N; Kamataki T; Kuroiwa Y
Drug Metab Dispos; 1996 Nov; 24(11):1212-7. PubMed ID: 8937855
[TBL] [Abstract][Full Text] [Related]
17. Identification of inhibitors of the nicotine metabolising CYP2A6 enzyme--an in silico approach.
Rahnasto M; Wittekindt C; Juvonen RO; Turpeinen M; Petsalo A; Pelkonen O; Poso A; Stahl G; Höltje HD; Raunio H
Pharmacogenomics J; 2008 Oct; 8(5):328-38. PubMed ID: 17923852
[TBL] [Abstract][Full Text] [Related]
18. Evidence for induced microsomal bilirubin degradation by cytochrome P450 2A5.
Abu-Bakar A; Moore MR; Lang MA
Biochem Pharmacol; 2005 Nov; 70(10):1527-35. PubMed ID: 16183037
[TBL] [Abstract][Full Text] [Related]
19. Diversity of selective environmental substrates for human cytochrome P450 2A6: alkoxyethers, nicotine, coumarin, N-nitrosodiethylamine, and N-nitrosobenzylmethylamine.
Le Gal A; Dréano Y; Lucas D; Berthou F
Toxicol Lett; 2003 Sep; 144(1):77-91. PubMed ID: 12919726
[TBL] [Abstract][Full Text] [Related]
20. More potent inhibition of human CYP2A6 than mouse CYP2A5 enzyme activities by derivatives of phenylethylamine and benzaldehyde.
Rahnasto M; Raunio H; Poso A; Juvonen RO
Xenobiotica; 2003 May; 33(5):529-39. PubMed ID: 12746108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
